Clonidine ameliorates Gilles de la Tourette syndrome.

Gilles de la Tourette syndrome (TS) is a severe, familial neuropsychiatric disorder of childhood onset that is characterized by multiform motor, phonic, behavioral, and psychological symptoms. Clonidine hydrochloride, a centrally active alpha-adrenergic agonist, was observed to ameliorate the disorder in the majority of 25 patients who could not tolerate or did not benefit from treatment with haloperidol. Clonidine had a gradual onset of action. Compulsive behavior, frustration intolerance, speech difficulties, behavioral blocking, attentional problems, and tics were responsive to treatment. The noradrenergic system may be involved, primarily or secondarily, in the expression of the genetic predisposition to TS. These observations will require testing by suitably controlled efficacy studies.
AuthorsD J Cohen, J Detlor, J G Young, B A Shaywitz
JournalArchives of general psychiatry (Arch Gen Psychiatry) Vol. 37 Issue 12 Pg. 1350-7 (Dec 1980) ISSN: 0003-990X [Print] UNITED STATES
PMID6255888 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Receptors, Adrenergic, alpha
  • Clonidine
  • Adolescent
  • Adult
  • Child
  • Clonidine (therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Middle Aged
  • Receptors, Adrenergic, alpha (drug effects)
  • Tourette Syndrome (drug therapy, psychology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: